 Home > Active Ingredient News > Antitumor Therapy > Melanoma seokons for post-treatment progress immunity after anti-PD-1/PD-L1 treatment: G protein estrogen receptor agonisant LNS8801 obtained FDA fast track

Melanoma seokons for post-treatment progress immunity after anti-PD-1/PD-L1 treatment: G protein estrogen receptor agonisant LNS8801 obtained FDA fast track

 Last Update: 2020-07-13
 Source: Internet
 Author: User

Tags

makeup cancer patients

body shrinking

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Linnaeus Therapeutics announced that the U.SFood and DrugAdministration (
FDA) has granted LNS88801 fast track designations for the treatment of metastatic or non-removable melanoma patients with disease progression after anti-PD-1 or anti-PD-L1 treatmentLNS8801 is currently being evaluated in a Phase 1 clinical trial for advanced cancer patientsThe company expects to begin its Phase 2 clinical study this year, with LNS8801 as a single therapy or a combination of targeted therapiesLNS8801 is a powerful agonisant that targets G-protein estrogen receptors (GPER)GPER is widely expressed in tumors, and excited GPER can both stop the spread of cancer and activate the body'simmuneresponseThe activity of LNS8801 depends on the expression level of the GPERGPER activation inhibits a variety of tumor-related genes, such as c-Myc and PD-L1In preclinical cancer models, LNS8801 exhibits strong antitumor activity in a wide range of tumor types, rapidly shrinking tumors and inducing immune memoryLNS8801 monotherapy has shown significant antitumor activity and has also shown a role when used in combination with targeted therapies, chemotherapy and immunotherapyLNS8801 is currently undergoing Phase 1/2 clinical trials in patients with advanced cancer in six comprehensive cancer centers in the United States

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.